1 / 37

Babesia in Florida: How Travel and Transfusion Facilitate Infection

Babesia in Florida: How Travel and Transfusion Facilitate Infection. Amber Barnes, MPH FL-EIS Fellow, Epidemiology Duval County Health Department. Presentation Objectives. To provide an overview of the current epizootiology of Babesia Describe routes of Babesia transmission

mike_john
Download Presentation

Babesia in Florida: How Travel and Transfusion Facilitate Infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Babesia in Florida: How Travel and Transfusion Facilitate Infection Amber Barnes, MPH FL-EIS Fellow, Epidemiology Duval County Health Department

  2. Presentation Objectives • To provide an overview of the current epizootiology of Babesia • Describe routes of Babesia transmission • Describe the potential impact of Babesia on Floridians

  3. Background of Babesiosis • Zoonotic infection of a protozoan parasite “Babesia” • causes “Babesiosis” • Transmitted through: • Ixodesscapularisdeer ticks • transfusion of infected blood products • and congenitally • Parasites invade the erythrocytes, or red blood cells • causes asymptomatic, acute, andchronicinfections

  4. Epidemiology of Babesia • There are over 100 known species of Babesia1 • The species known to parasitize in humans include:2 • B. microti is the most common species to cause infection in humans in America • B. divergens is the most common species infecting humans in Europe • - B. microti - B. duncani • - B. microti-like - B. duncani-like • B. divergens - B. ovis-like • B. divergens-like - B. bovis • - B. canis

  5. Transmission • Ixodes scapularis- black-legged deer tick • Larval stage= feeds on white-footed mouse • Nymphal stage= feeds on humans and white-tailed deer DIME From http://fubyss.ento.vt.edu/vagm/enemies.html From http://www.ent.iastate.edu/imagegal/ticks/iscap/

  6. Transmission B. microti transmission Life Cycle of I. scapularis tick RESEVOIR: White footed mouse and other rodents VECTOR/ PRIMARY HOST: Black-legged deer tick SECONDARY HOST: mammals, i.e. humans Courtesy of D.W. Miller within Vannier, et al. Infectious Disease Clinics of N. America 22 (2008) 469–488.

  7. Life Cycle of Babesia Some Babesia species are transmitted at every stage of the tick’s life Reprinted with gracious permission from K.-P Hunfeld et al. International Journal for Parasitology 38 (2008) 1219-1237as modified from Mehlhorn and Piekarski, 2002.

  8. Transmission • Additional transmission routes: • congenital/perinatal infection to baby • transfusion of blood from an infected donor • donor may be asymptomatic • currently no testing for Babesia in donated blood products or screening of blood product donors • parasite can survive for 35 days in refrigerated blood bank conditions3 • patients receiving blood are immunocompromised or immunosuppressed

  9. Infection • Asymptomatic infection • majority of cases are unaware of infection • parasitemia levels may be too low for detection • Chronic infection • can be infected for months, even years4 • infected blood donors can transmit disease unknowingly • infected mothers have infected unborn babies and newborns • Acute infection • can cause severe illness and death • primarily affects immunocompromised/suppressed • especially asplenic and/or elderly patients5

  10. Clinical Symptoms • “Malaria-like” infection6 • Common symptoms: • Additional symptoms may include: • Fever Fatigue • Chills Hemolytic anemia • Myalgia Jaundice secondary to anemia • HeadacheVomiting • Anorexia Thrombocytopenia • Nausea Normal or low WBC count

  11. Infection • Most untreated infections will resolve but can take weeks to several months • Incubation Period of Babesiosis: • ranges from 1 week to several months • generally shorter for tick-borne transmission • can be longer for transfusion transmission • Period of Communicability: • very rare person-to-person transmission: • congenital/perinatal • transfusions of infected blood

  12. Diagnosing Babesiosis **CURRENTLY NOT REPORTABLE IN FLORIDA** • Can be difficult to diagnose • Things to remember… • Babesia is not endemic to our area • may not be considered in the differential diagnosis • Babesia is often discovered by our state labs testing blood for malaria • different Babesia species show up through different diagnostic methods

  13. tetrad Diagnosing Babesia • Diagnosed through the identification of the intraerythrocitic parasites on Giemsa- or Wright-stained thick or thin blood smears7 • can be very difficult to distinguish from Plasmodium falciparum • look for the disease-specific “Maltese cross” • only visible during Merozoite stage

  14. Diagnosing Babesia • Once identified, more serologic and molecular testing is performed by: • a reference laboratory • confirms diagnosis • CDC’s parasitology lab • confirm diagnosis • and/or determine species • animal innoculation • can take up to two weeks for results8

  15. Guess That Parasite! B. microti B. microti B. divergens B. divergens B. venatorum B. venatorum B. venatorum P. vivax P. falciparum Images courtesy of the Liverpool School of Tropical Medicine and arrow sources from Häselbarth et al 2007 and Hildebrandt et al 2008.

  16. Treatment • Asymptomatic infection is rarely treated • General recommended treatment for immunocompetent individuals includes: • Clindamycin + PLUS • Quinine or Quinidine • 7 to 10 day treatment • can result in side effects that merit use of alternative drugs

  17. Treatment • Recommended treatment for individuals immunocompromised or those with very high parasitemia levels includes: • Azithromycin + PLUS • Atovaquone • 7 to 10 day treatment • some research indicates new resistance9 • In rare instances of severe infection, exchange transfusions are given10

  18. Wisconsin Case Definition Example • Confirmed Babesiosis: • A clinically compatible illness that is laboratory confirmed. OR • A patient who is lab-confirmed or who would meet the serology criteria of a probable case, regardless of symptomatology, who is epidemiologically linked to a confirmed case acquired via transfusion

  19. Wisconsin Case Definition Example • Probable Babesiosis: • A clinically compatible illness with demonstration of a Babesia-specific antibody titer of at least 1:256 with an indirect fluorescent antibody (IFA) test for total Ig or IgG. The titer should be at least 1:1024 for infection with WA1-type parasites. • Comments:Confirmation of the diagnosis of babesiosis by a reference laboratory is strongly encouraged. The validity of the diagnosis of babesiosis is highly dependent on the laboratory that does the testing. For example, differentiation between malaria and Babesia parasites on peripheral blood smears can be very difficult. From http://hanplus.wisc.edu/epinet/reports/CDES101_babesia.pdf

  20. Cases Examples • Case #1: Wedding-acquired Babesiosis in NY • 73 y/o female • Arrived at ED after passing out in her doctor’s waiting room • Had fever at night for last two weeks and anemia • Exposure risk: • Previous month she had traveled to Connecticut for an outdoor wedding • No memory of a tick bite • RBC transfusion at hospital • Peripheral smear showed parasites • Considered malaria at first • B. microti was confirmed instead • Treated successfully with a 14 day course of Atovaquone and Azithromycin11

  21. Cases Examples • Case #2: Probable congenital in NJ • 26 day old infant • Transferred to hospital for evaluation • Complaints of fever, hyperbilirubinemia, not feeding well, irritable, and gagging • Mother, a migrant crop worker, noticed the infant had yellow eyes • Exposure risks: • No travel by mom or baby • No tick exposure to child • Mother had been bitten by two ticks while 8 months pregnant • RBC transfusion at hospital • Peripheral blood smear discovered B. microti • Treated successfully with Atovaquone and Azithromycin12

  22. Florida Cases • Case #3: Probable transfusion transmitted • 74 y/o male • Arrived at ED on 4/11/2009 • Complaints of anemia and syncope • Patient had a recent aneurysm repair • Parasites present on peripheral smear • malaria test was conducted on 4/12/2009 • Results were positive for Babesia, negative Malaria • B. microti IgM level was <1:10 with the range being Neg: <1:10 • B. microti IgG level was Neg. >1:320 with the range being Neg: <1:10 • Negative IgM and positive IgG serology may indicate a pervious or current babesiosis infection

  23. Florida Cases • Case #3 Cont.: Probable transfusion • DSI Laboratory reviewed the specimen and confirmed it was Babesia • Exposure risks: • No memory of tick bite • No travel outside of the U.S. in >50 years • Transfusion history in past year • Reported internally with the blood bank in April and to the FDOH in September

  24. Florida Cases • Case #3 Cont.: Probable transfusion • Total of 27 different donors were used for patient • 17 donors subsequently tested negative • 10 were lost to follow up

  25. Florida Cases • Case #4: Travel and transfusion exposures • 60 y/o male • Arrived at ED on 8/28/09 • Complaints of dizziness, intermittent fevers, fatigue, and several falls • Once admitted, patient had severe anemia, thrombocytopenia, leukopenia and severe abdominal pain • CT scan found patient had a lacerated spleen • Patient underwent a splenectomy and transfusion • 6 units of RBCs and 2 units of platelets administered 8/28/09 through 9/5/09

  26. Florida Cases • Case #4 Cont.: Travel/transfusion exposures • Patient developed a post-op fever • Blood smears interpreted as possible malaria • State lab looked at smears at suspected babesiosis • Specimens forwarded to CDC’s Parasitology Lab • Confirmed B. microti diagnosis • Exposure risks: • Travel to Massachusetts for 5 weeks with a return date of 8/1/09 • No known tick bites • No confirmed previous Babesia infection • Transfusion history in past year • Blood bank attempted to inform donors of potential infection • Patient treated with Azithromycin and Atovaquone

  27. Florida Cases • Case #5: Confirmed transfusion exposure • 84 y/o male • Admitted to hospital in February, 2008 with a GI bleed • Given RBC and plasma transfusions due to surgical repair • Patient returned to hospital 3/18/08 • Complained of fever, chills, diarrhea, sweats, back pain, and anorexia • Peripheral blood smear at hospital was suspect for malaria • State lab confirmed sample was negative for malaria but positive for B. microti • Patient treated successfully and recovered

  28. Florida Cases • Case #5 Cont.: Confirmed transfusion exp. • Blood banks did a trace back to find infected donor • 3 units of blood and 2 units of plasma given 2/8 and 2/11 • 3 separate RBC donors • 2 Florida residents • 1 vacationing Wisconsin resident • FDOH developed questionnaire based on Babesia forms from endemic states for blood bank to use • Found Wisconsin donor to be infected • Donor was asymptomatic • Owned a cabin in the woods of an endemic state • Donated here and in home state of Wisconsin • Wisconsin blood banks had to be notified of donor’s status • Upon diagnosis, donor was reported in Wisconsin state data

  29. Expanding Babesia Range • Residential development in tick-prone wooded areas • More interaction with a growing population of deer11 • B. microti is already endemic and reportable in: • Northeastern United States • Connecticut • Massachusetts • New Jersey • New York • Rhode Island • Upper Midwestern United States • Wisconsin • Minnesota • Prior travel history to these areas may indicate potential exposures in cases

  30. Expanding Babesia Range • Prior to 2001, most NY cases were residents of Long Island or those with travel to endemic areas • In 2001, there were 5 confirmed locally-acquired cases in residents of the Lower Hudson Valley, north of the endemic area with no travel or recognized risk factors • NY Dept. of Health collected 1,139 I. scapularis ticks from 5 areas in the Lower Hudson Valley and found B. microti • Babesia is moving up the state13 Reprinted with from Kogut et al. Emerging Infectious Diseases 11, 3 (2005).

  31. Expanding Babesia Range Table 1: Important Babesia spp. with zoonotic potential including recently recognized defined parasites a Known to regularly parasitize humans; ?: unknown; (?): questionable. b Unverified infections with B. canis and B. bovis have been reported (Gorenflot et al., 1998), though it is likely that B. bovis infections are in fact B. divergens. Reprinted with gracious permission from K.-P Hunfeld et al. International Journal for Parasitology 38 (2008) 1219-1237.

  32. Surveillance • The FDA, CDC, CSTE, and other public health organizations have recently determined transfusion-transmitted Babesia to be a major public health concern • Florida is currently discussing how best to investigate future Babesia cases, especially in regard to transfusion transmitted cases • A draft of a Standard Operating Procedure for Babesia case follow up in Florida residents will be completed in the coming months

  33. Preventing Tick-borne Infection • Use protective measures when outdoors • avoid tick-prone areas May through October • choose light colored clothing • wear long sleeves and pants • tuck pants into boots • use tick and insect repellents that contain DEET • inspect yourself for ticks • if you find one, remove it with clean tweezers by gently pulling it straight away from the body, not twisting, and wash the area immediately14 • provide your pets monthly tick prevention medications

  34. Questions? Courtesy of http://giveavoice.files.wordpress.com/2009/06/questions.jpg

  35. References for Slide Material 1Gray, J.S., Weiss, L.M. 2008. Babesia microti. In: Khan, N. (Ed.), Emerging Protozoan Pathogens. Taylor and Francis, Abingdon, UK, pp. 303-349. 2Hunfeld, K.-P. et al., 2008. Babesiosis: Recent Insights into an Ancient Disease. International Journal for Parasitology, 38, 1219-1237. 3Emerging Health Threats Forum. (2009). Babesiosis: call for better blood screening. Retrieved on March 23rd, 2010 from http://www.eht-forum.org/news.html?targetPage=news/fulltext/news091023073616.html&from=search. 4Dobroszycki, J. et al., 1999. A Cluster of Transfusion-Associated Babesiosis Cases Traced to a Single Asymptomatic Donor. JAMA, 281(10), 927-930. 5Heymann, D.L. 2008. Babesiosis. In. Heymann, D.L. (Ed.), Control of Communicable Diseases Manual. American Public Health Association, Washington, D.C., USA, p.p.69-72. 6Weld, E.D., Eimer, K.M., Saharia, K., Orenstein, A., & Hess, J.R. 2010. The expanding range and severity of babesiosis. Transfusion 50, 290-291. 7Pickering, L.K. 2009. Babesiosis. In. Pickering, L.K., Baker, C.J., Kimberlin, D.W., Long, S.S., (Eds). Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. American Academy of Pediatrics, Elk Grove, IL, USA. p.p. 226-227. 8Asad, S., Sweeney, J., & Mermel, L.A., 2009. Transfusion-transmitted babesiosis in Rhode Island. Transfusion, 49(12), 2564-2573. 9Wormser, G.P., et al. 2010. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 50, 381-386. 10Leiby, D.A. 2006. Babesiosis and blood transfusion: flying under the radar. Vox Sanguinis 90, 157-165. 11Rawling, R.A., et al. 2009. A Case of Wedding-Acquired Babesiosis. Clinical Microbiology Newsletter 31(15), 116-118. 12Sethi, S. et al., 2009. Probable Congenital Babesiosis in Infant, New Jersey, USA. Emerging Infectious Diseases, 15(5) 13Kogut, S.J. et al., 2005. Babesiamicroti, Upstate New York. Emerging Infectious Diseases, 11(3). 14American Lyme Disease Foundation, Inc. (2010). Lyme Disease, How to Remove a Tick. Retrieved March 23rd, 2010 from http://www.aldf.com/lyme.shtml#removal.

  36. References for Graphics and Table • http://fubyss.ento.vt.edu/vagm/enemies.html • http://www.ent.iastate.edu/imagegal/ticks/iscap/ • D.W. Miller within Vannier, E. et al., 2008. Human Babesiosis. Infectious Disease Clinics of N. America 22, 469- 488. • K.-P Hunfeld et al., Babesiosis: Recent Insights into an Ancient Disease. International Journal for Parasitology, 38, as modified from Mehlhorn, H. & Piekarski, G., 2002. Grundriß der Parasitenkunde, 6th revised edition. Spektrum Akademischer Verlag GmbH, Heidelberg, Berlin, Germany, pp. 38-39. • ASM http://www.MicrobeLibrary.org • Liverpool School of Tropical Medicine and arrow sources from Häselbarth, K. et al., 2007, First Case of human babesiosis in Germany- Clinical presentation and molecular characterization of the pathogen. International Journal of Medical Microbiology 297, 197-204 and Hildebrandt, A. et al., 2008, Human babesiosis in Germany: Just overlooked or truly new?. International Journal of Medical Microbiology 298, 336-346. • http://hanplus.wisc.edu/epinet/reports/CDES101_babesia.pdf • Kogut, S.J. et al., 2005. Babesiamicroti, Upstate New York. Emerging Infectious Diseases, 11(3). • http://giveavoice.files.wordpress.com/2009/06/questions.jpg

  37. Contact Information Amber Barnes, MPH EIS Fellow, FL DOH (904) 253-1864 Amber_Barnes@doh.state.fl.us Robyn Kay, MPH Regional Epidemiologist, FL DOH (904) 791-1747 Robyn_Kay@doh.state.fl.us Danielle Stanek, DVM Medical Epidemiologist, FL DOH (850) 294-1087 Danielle_Stanek@doh.state.fl.us Beth Radke, MPH Arbovirus Surveillance Coordinator, FL DOH (850) 245-4444 ext. 2437 Elizabeth_Radke@doh.state.fl.us Please visit the CDC’s website on Babesiosis at http://www.cdc.gov/babesiosis/ for more information.

More Related